As part of a regular review of safety reports for the vaccine, the European Medicines Agency’s safety committee is analysing data provided on cases of Guillain-Barre syndrome, the regulator said.
It comes as some European countries have restricted use of the AstraZeneca jab to older age groups, citing the risks of rare blood clots in younger people.
MORE TO FOLLOW
